LOS ANGELES, Nov. 13, 2014 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, is pleased to announce the appointment of Dr. Andrew Berman as the Medical Director of the advisory board.
Dr. Andrew Berman, M.D., MPH, is a Beverly Hills, California doctor affiliated with area hospitals including Cedars Sinai Medical Center and Midway-Olympia Hospital. Dr. Berman received his medical degree from Chicago Medical School and is an associate of the American Academy of Otolaryngology, the American Academy of Facial Plastic and Reconstructive Surgery, and the International Association of Plastic, Aesthetic and Reconstructive Surgery. Dr. Berman's interests are in otolaryngology and ear, nose and throat conditions, with a clinical interest in diabetes mellitus.
"Dr. Berman has spent years serving the Beverly Hills area and greater California, and we're eager to utilize his medical expertise in developing potential applications and expanding the range of ViaDerma's proprietary transdermal delivery system," said Dr. Christopher Otiko, CEO of ViaDerma.
Dr. Berman is the first of many reputable professionals to be appointed to the ViaDerma advisory board which began recruiting this fall. The board will advise and consult on ViaDerma's business development efforts and provide strategic support to grow market awareness for the company and its products including research and development, sales, marketing and licensing opportunities. The board serves as an important step in furthering ViaDerma's innovative technology and securing the company's position as an industry leader.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
Forward Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. Christopher Otiko Chief Executive Officer ViaDerma, Inc. firstname.lastname@example.org 818-836-2475 Kristi Hofacker Director of Interactive Marketing & Media The Brewer Group email@example.comSource:ViaDerma Licensing